EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release.

about

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release.

Item

http://www.wikidata.org/entity/Q42030787

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

EGFR or HER2 inhibition modula ...... f PD-L1 and cytokines release.

@en

EGFR or HER2 inhibition modula ...... f PD-L1 and cytokines release.

@nl

type

Item

label

EGFR or HER2 inhibition modula ...... f PD-L1 and cytokines release.

@en

EGFR or HER2 inhibition modula ...... f PD-L1 and cytokines release.

@nl

prefLabel

EGFR or HER2 inhibition modula ...... f PD-L1 and cytokines release.

@en

EGFR or HER2 inhibition modula ...... f PD-L1 and cytokines release.

@nl

P1476

EGFR or HER2 inhibition modula ...... f PD-L1 and cytokines release.

@en

P2093

Ahrum Min

http://www.w3.org/2001/XMLSchema#string

Jee Hyun Kim

http://www.w3.org/2001/XMLSchema#string

Jeong-Ok Lee

http://www.w3.org/2001/XMLSchema#string

Ji Eun Kim

http://www.w3.org/2001/XMLSchema#string

Ji Hea Sung

http://www.w3.org/2001/XMLSchema#string

Ji-Won Kim

http://www.w3.org/2001/XMLSchema#string

Jin Won Kim

http://www.w3.org/2001/XMLSchema#string

Jong Seok Lee

http://www.w3.org/2001/XMLSchema#string

Keun-Wook Lee

http://www.w3.org/2001/XMLSchema#string

Koung Jin Suh

http://www.w3.org/2001/XMLSchema#string

P2860

Interaction of tumor cells with the microenvironment

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

The chemokine superfamily revisited

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.

PD-1 and its ligands in tolerance and immunity

Comprehensive molecular characterization of gastric adenocarcinoma

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

P304

63901-63910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19194

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hye Seung Lee

Se Hyun Kim

P577

2017-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28969039

http://www.w3.org/2001/XMLSchema#string

P932

5609971

http://www.w3.org/2001/XMLSchema#string